Search the Newsreel

We Might See A Profit From Everest Medicines Limited (HKG:1952) Soon

Cintas (CTAS) Names Jim Rozakis President

Cintas (NasdaqGS: CTAS) has announced a leadership change, appointing Jim Rozakis as President while Todd Schneider remains CEO, formally separating the two roles. This move signals a new executive structure for the company, aiming to clarify the split between high-level direction and day-to-day operations …

Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next

Revolution Medicines (RVMD) reported a significant net loss in Q2 2026, yet its stock rose by 9.4% due to advancing daraxonrasib through FDA review for metastatic pancreatic cancer and high compassionate use demand. Over 2,000 patients have received daraxonrasib, indicating strong real-world interest, and …

Raily Aesthetic Medicine Issues Positive Profit Alert with Revenue and Profit Turnaround for H1 202612

nCino’s Mortgage MCP: A Major shift for Lenders in AI Integration

nCino has launched Mortgage MCP (Model Context Protocol), integrating AI agents directly into mortgage workflows. This move aligns with high enterprise demand for agentic AI, with a significant percentage of buyers prioritizing autonomous agents. The product aims to provide a structured interface for deploying …

Gradient Investments LLC Grows Position in Cintas Corporation $CTAS

Gradient Investments LLC increased its stake in Cintas Corporation (NASDAQ:CTAS) by 21.8% in the second quarter, bringing its total holding to $21.56 million. Institutional investors now own 63.46% of the company. Cintas exceeded earnings expectations, with strong revenue growth, and analysts maintain a "Moderate …

Disc Medicine Investor News: If You Have Suffered Losses in

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. Investors who suffered losses are encouraged to contact the firm regarding a …

Parabilis Medicines, Inc. - Common Stock (Nasdaq:PBLS) Stock Quote

This article provides a stock quote and related news for Parabilis Medicines, Inc. (PBLS). It includes current trading information, performance data, and recent news headlines highlighting the company's IPO success and insider stock purchases, indicating significant interest and investment in the biotech firm.

Cintas Corporation $CTAS Shares Bought by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Cintas Corporation (NASDAQ:CTAS) by 8.7% in the second quarter, bringing its total holdings to 69,891 shares valued at approximately $11.9 million. Cintas has exceeded quarterly expectations with $1.29 adjusted EPS and $2.91 billion in revenue, and has issued …

Quantinno Capital Management LP Purchases 208,336 Shares of nCino Inc. $NCNO

Quantinno Capital Management LP significantly increased its stake in nCino Inc. by 208.4% in the first quarter, purchasing 208,336 shares to bring its total holdings to 308,294 shares valued at $4.62 million. Institutional investors now own 94.76% of nCino, reflecting strong participation, despite recent …

Cinemark Holdings Inc $CNK Shares Sold by First Trust Advisors LP

First Trust Advisors LP reduced its stake in Cinemark Holdings Inc ($CNK) by 41.8% in the first quarter, selling over 65,000 shares but still retaining about 90,000 shares valued at $2.6 million. Despite this sale, other institutional investors increased their positions, and Wall Street …

nCino (NCNO) Stock Looks Above Fair Value Despite Sales That Hold Up

nCino's stock appears overvalued based on its P/S ratio of 3.4x, which is above its estimated fair ratio of 2.6x and slightly above its peer average. Despite a significant 69.0% share price decline over five years, recent product news like Mortgage MCP with AI …

Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Prime Medicine (NASDAQ:PRME) from a "strong sell" to a "sell" rating, while other analysts maintain a "Moderate Buy" consensus with an average price target of $7.53. The company's shares opened at $3.08, significantly below its 52-week high, and it met …

Disc Medicine Chief Legal Officer Rahul Khara disposes of 5,000 common shares for $400,000

Disc Medicine's Chief Legal Officer, Rahul Khara, sold 5,000 common shares for $400,000 on August 6, following the exercise of 5,000 stock options. After these transactions, Khara directly held 52,324 shares and 49,804 stock options. This information was generated by AI from an SEC …

nCino, Inc.

nCino, Inc. announced new Mortgage MCP capabilities, allowing lenders to connect AI agents directly to the nCino Mortgage Suite using the Model Context Protocol. This aims to streamline mortgage workflows for administrators and loan officers by enabling natural language commands and automating tasks within …

Amundi Acquires Shares of 322,516 nCino Inc. $NCNO

Amundi has acquired 322,516 shares of nCino Inc. (NASDAQ:NCNO) in the first quarter, valued at approximately $4.83 million, establishing a 0.30% stake in the company. Despite recent insider sales totaling about 67,222 shares, largely for tax obligations, analysts maintain a "Moderate Buy" consensus rating …

MediciNova Inc expected to post a loss of 6 cents a share - Earnings Preview

MediciNova Inc is projected to report a loss of 6 cents per share in its upcoming earnings. This information comes from a Refinitiv earnings preview. The full article provides more details on this financial forecast.

MNOV Q2'26 Earnings: revenue estimate is 75.00K USD

MediciNova, Inc. (MNOV) is expected to announce its Q2'26 earnings on August 14, with an estimated revenue of $75.00 thousand USD and an anticipated EPS of ($0.06) USD. The company's past reported revenues and EPS for previous quarters are also provided for comparison.

Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold

Wall Street Zen has upgraded Editas Medicine (NASDAQ:EDIT) from "sell" to "hold." Despite this, broader analyst coverage remains "Moderate Buy" with a consensus price target of $5.40. The company recently surpassed quarterly earnings and revenue expectations, although company insiders have sold shares while institutional …

Lipocine Inc (LPCN) Stock News Today

This page provides recent news and analysis for Lipocine Inc (LPCN) stock. It includes current stock price, market cap, and a note that more news is coming soon, urging users to stay tuned. The article primarily serves as a placeholder for future news updates …

Disc Medicine Insider Sold Shares Worth $400,000, According to a Recent SEC Filing

An insider at Disc Medicine recently sold company shares valued at $400,000, as disclosed in a recent SEC filing. The transaction indicates a significant insider sale, which could be of interest to investors monitoring the company's stock. Further details would typically be available in …

Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statement

Editas Medicine director Ellinor Patrick Thomas II has filed an initial beneficial ownership statement (Form 3) with the SEC, dated August 6. This filing indicates that Thomas is now a reporting owner for the company. The news brief was generated by Public Technologies (PUBT) …

Scinai Immunotherapeutics Ltd (SCNI) Stock News Today

This article provides an overview of Scinai Immunotherapeutics Ltd (SCNI) stock information from TradingKey. It shows the current stock price, recent performance, market capitalization, and various financial and analytical tools available on the platform. The news section indicates that more updates are expected soon.

Scinai Immunotherapeutics Ltd (SCNI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Scinai Immunotherapeutics Ltd (SCNI), noting that no specific earnings forecast score is available for the company, contrasting with the Biotechnology & Medical Research industry average. It highlights the current stock price, market capitalization, and indicates that relevant …

Is Cintas (CTAS) Fairly Valued After Its Leadership Reshuffle?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Cintas (CTAS) recently drew investor attention after separating the roles of president and chief executive officer and appointing Jim Rozakis as president and COO, …

nCino, Inc. (NCNO) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive information on nCino, Inc. (NCNO) stock, including its current price, historical data, financial performance, and analyst insights. The company offers software-as-a-service solutions to financial institutions, covering various aspects like onboarding, account opening, and lending. The stock is currently …

Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 5,000 Shares

Disc Medicine insider Rahul Khara sold 5,000 shares of the company's stock for $400,000, reducing his direct ownership by 8.72% to 52,324 shares. The company recently reported a quarterly loss of $1.54 per share, beating analyst expectations, and has a "Moderate Buy" consensus rating …

How Cincinnati Financial Corporation (CINF) Affects Rotational Strategy Timing

This article analyzes Cincinnati Financial Corporation (CINF) using AI models, suggesting a near-term strong sentiment transitioning to mid-term neutrality and a long-term positive bias. It highlights a significant 21.7:1 risk-reward setup, targeting a 6.2% gain against a 0.3% risk. The analysis provides specific trading …

Rahul Khara, Disc Medicine CLO, sells $400,000 in shares

Rahul Khara, Chief Legal Officer at Disc Medicine Inc. (IRON), sold 5,000 shares worth $400,000 on August 6, 2026, while also acquiring 5,000 shares through stock option exercise for $73,450. These transactions were part of a Rule 10b5-1 trading plan. Following these sales, Khara …

Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000

Editas Medicine (NASDAQ: EDIT) reported that director Ellinor Patrick Thomas II was granted 103,400 stock options with an exercise price of $2.9000 per share, expiring on August 5, 2036. These options vest in three equal annual installments starting August 6, 2027. Following this grant, …

Editas Medicine, Inc. (EDIT) director reports no share or option holdings

A director at Editas Medicine, Inc. (EDIT), Ellinor Patrick Thomas II, has filed an initial beneficial ownership report (Form 3) disclosing no holdings of common stock or derivative securities. The filing indicates no insider transaction activity, such as purchases or sales, associated with this …

Disc Medicine (NASDAQ: IRON) CLO sells 5,000 shares after option exercise

Disc Medicine, Inc.'s Chief Legal Officer, Rahul Khara, exercised 5,000 stock options at $14.69 per share and subsequently sold 5,000 common shares at $80.00 per share on August 6, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March …

'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug

Revolution Medicines is preparing for the potential launch of its pancreatic cancer drug, daraxonrasib. The Redwood City-based company, led by CEO Mark Goldsmith, boasts a substantial financial reserve of $3.9 billion in cash and equivalents, positioning it strongly among mid-size biotechs for this significant …

Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options

Lipocine Inc. (NASDAQ: LPCN) director Michael Grissinger was awarded 2,000 stock options on August 3, 2026, with an exercise price of $2.11 per share and an expiration date of August 3, 2036. The options have a vesting schedule, with one-third vesting on August 3, …

Lipocine Inc. (LPCN) director Grissinger files initial ownership statement

Lipocine Inc. director Michael Grissinger has filed an initial statement of beneficial ownership (Form 3). This filing indicates that Grissinger is a director but not an officer or a ten percent owner of the company, and it reports no current equity holdings or insider …

Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside

Praxis Precision Medicines, Inc. (PRAX) has seen its average 12-month stock price target raised to $620.95 by 19 analysts, up from $604.83. This new target suggests a potential upside of approximately 95% from its recent closing price. The consensus analyst rating for PRAX remains …